Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
OrbiMed-incubated Pinnacle Medicines is featured at the Boston peptide summit highlighting its oversubscribed $89M Series B financing (closed March 26) for advancing oral peptide therapeutics designed to match the efficacy of injectable biologics. Lead programs target asthma, COPD, immunology, and inflammation — distinct from the GLP-1 obesity focus dominating peptide headlines. The platform combines proprietary peptide stabilization with oral-bioavailability engineering, positioning Pinnacle as one of the most differentiated non-GLP-1 oral peptide developers in the current pipeline.
Daiichi Sankyo's collaboration with Meddenovo's AI-powered Mexa technology — for de novo design of cyclic peptides — is among the highlighted partnerships at the Boston peptide summit. The deal positions Daiichi to leverage Meddenovo's machine-learning platform for peptide candidates beyond the company's traditional small-molecule oncology focus. Cyclic peptide AI design is one of the fastest-moving subcategories in peptide drug discovery, with Circle Pharma, Bicycle Therapeutics, and Unnatural Products all pursuing distinct platform architectures.
Morningstar issued a pre-earnings note ahead of Eli Lilly's April 30 Q1 2026 report raising fair value to $870 from $770 following 2025 results and management guidance. Analysts project 27% top-line growth in 2026 and 20% in 2027, with double-digit growth through end of decade. Mounjaro/Zepbound represented 56% of total sales in 2025, projected to exceed 60% in 2026 with patent protection through 2036. The Q1 print will be the first read on Foundayo launch trajectory after the disappointing 1,390 / 3,707 prescription weeks 1-2.
C&EN published a comprehensive April 2026 feature examining whether amylin analogs — Novo's cagrilintide, Lilly's eloralintide, and Roche/Zealand's petrelintide — can carve meaningful share in a market dominated by semaglutide and tirzepatide. Wall Street initially expected amylin candidates to differentiate on muscle preservation and reduced GI side effects, but as Phase 2 readouts arrive investor enthusiasm has cooled. CagriSema Phase 3 head-to-head against tirzepatide is the make-or-break readout for Novo Nordisk's amylin strategy.
An investor-facing April 2026 deep dive analyzes Hims & Hers' transformation from compounded GLP-1 distributor to dual-supplier branded telehealth platform after the Novo Nordisk settlement (March 9, 2026), the Eli Lilly partnership expansion (April 23), and the FDA Category 2 peptide reclassification. The piece argues the California peptide manufacturing facility acquired in 2025 — originally for compounded GLP-1s — could pivot to producing reclassified peptides like BPC-157, TB-500, and KPV if July's PCAC clears the path.
Two of the largest obesity drug makers report this week: Eli Lilly (April 30) with Foundayo (orforglipron) launch trajectory and Mounjaro/Zepbound dynamics under scrutiny — Lilly previously guided 2026 sales of $80-83 billion (25% growth); and Novo Nordisk (May 6) facing 5-13% guided sales decline as semaglutide loses exclusivity in China, Brazil, Canada, and as the Wegovy pill ramps. Goldman analysts model Lilly's oral GLP-1 capturing 60% of the daily-oral segment by 2030; Novo's projected at 21%. The Foundayo Week 1-2 prescription tracker has shown a slow start.
Empower Pharmacy published a detailed industry analysis of the FDA's April 16 announcement removing 12 peptides from Category 2 and convening the July 23-24 PCAC meeting. The piece walks through the practical implications for compounding pharmacies, distinguishes Category 2 removal from Section 503A Bulk Drug Substances List inclusion, and emphasizes the gap between regulatory action and clinical access — physicians and patients are pressuring compounders to prepare peptides legally restricted only weeks ago.
Hims & Hers' announced $1.15 billion acquisition of Eucalyptus continues to be a major catalyst for the company alongside Friday's JPMorgan Overweight upgrade. Eucalyptus brings Australia and Japan exposure, with management targeting more than $1 billion in annual international revenue within three years. Combined with the recent Eli Lilly LillyDirect partnership (Foundayo, Zepbound, KwikPen) and the FDA peptide reclassification framework, Hims now has three strategic catalysts reshaping its 2026 trajectory.
Hims & Hers announced April 23 a strategic expansion of its U.S. weight loss platform, adding licensed-provider prescriptions for Eli Lilly's Zepbound vials, Zepbound KwikPen, and Foundayo. Prescriptions are fulfilled through LillyDirect pharmacy, completing a dual-supplier arrangement after last month's Novo Nordisk Wegovy collaboration. Shares jumped roughly 7% on the announcement as investors digested the company's pivot from compounded GLP-1s toward branded distribution.
JPMorgan initiated coverage of Hims & Hers on April 24 with an Overweight (Buy-equivalent) rating and a $35 price target, citing the Novo Nordisk and Eli Lilly partnerships, progress toward peptide legalization, and a likely revenue rebound in H2 2026. Shares jumped about 9.6% intraday Friday, representing roughly 25% upside from Thursday's close. The note specifically called out the Novo Nordisk deal as 'a turning point' that resolves the company's prior legal overhang from compounded GLP-1 production.
Cerapedics, Inc. announced April 24 a supplier agreement with Vizient for PearlMatrix® P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product for adult patients with degenerative disc disease in the lumbar spine. The deal extends access to Vizient's network of academic medical centers, community hospitals, and integrated health delivery networks. PearlMatrix uses a 15-amino-acid peptide (a fragment of Type I collagen) bound to anorganic bone mineral as a bone growth accelerator — one of the few peptide-enhanced devices on the U.S. orthopedics market.
A Drug Discovery News feature surveyed the emerging hair loss treatment landscape and asked whether the category could replicate the GLP-1 obesity drug breakout. Lead candidates include Pelage Pharmaceuticals' PP405 (small-molecule topical, Phase 3 launch 2026 with FDA approval potentially 2027-2029), the MLPH peptide (preclinical, novel safe mechanism for both sexes), the APN5 peptide (Korean research team, hair growth + suppression of loss), and product launches from Ouai Haircare's $50 Bond Repair Balm and Omi Well Beauty's Hair Growth Peptides expanding the consumer category.
Roche reported Q1 2026 sales up 6% at constant exchange rates and used the earnings call to re-anchor its obesity strategy. Executives project $9 billion in peak annual sales from the emerging breast cancer pill plus four obesity candidates. Lead asset petrelintide (licensed from Zealand Pharma, ZUPREME-1 Phase 2 showed up to 10.7% weight loss with placebo-like tolerability) is positioned at a differentiated patient segment. CEO Schinecker said Roche is not investing in the first generation of obesity drugs, but the next — with petrelintide and CT-388 (enicepatide) data headed for ADA 2026.
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
Clean luxury skincare brand SVEDA launched its Renewal Peptide Serum ($124.99) on April 24. The formulation pairs caviar extract and hydrolyzed pearl (providing amino acids and trace minerals supporting collagen synthesis) with bakuchiol (a plant-derived retinol alternative), green tea hydrosol, Tsubaki seed oil, and grass-fed beef tallow. The launch lands in a broader consumer-peptide boom — 'peptide therapy' search interest is up 281% YoY on Google, 459% on TikTok, and 412% on Instagram as cosmetic brands rush to capture the mainstreaming trend.
Ahead of Amgen's April 30 Q1 2026 earnings release, analyst coverage highlighted MariTide as the company's most closely-watched pipeline asset. The bispecific GLP-1 RA / GIPR antagonist delivered up to 20% weight loss at 52 weeks in Phase 2 and is now enrolled across six global Phase 3 trials — with monthly, bi-monthly, and potentially quarterly dosing as its primary commercial differentiator against weekly GLP-1s. Amgen recorded $35.1 billion in 2025 product sales (+10%), and MariTide headline data from the Phase 3 program is expected to begin reading out in 2027.
MBX Biosciences announced an April 23 press release confirming its May 11 virtual Obesity Day event, at which the company will formally update investors on its Precision Endocrine Peptide (PEP) platform. The portfolio includes MBX 4291 (Phase 1 GLP-1/GIP co-agonist prodrug designed for once-monthly dosing), an amycretin prodrug with Q2 2026 nomination expected, and a GLP-1/GIP/GCGR triple agonist prodrug with Q3 2026 nomination — all targeting once-monthly administration. Richard DiMarchi and Katherine Saunders will headline the event.
Canadian-listed The Precision Peptide Company (CSE:BPC) announced April 23 a six-month strategic product marketing agreement with UK-based creative agency Raw Creation for CAD$85,500 total (CAD$9,000 setup plus CAD$76,500 retainer), rolling to CAD$15,000/month afterward. The deal covers social media management, creative and video production, editorial and press services, and paid advertising — an early indicator that small-cap peptide-focused companies are investing in consumer marketing infrastructure as the category enters mainstream awareness.